Results 11 to 20 of about 6,039,132 (349)

Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition

Multiple Sclerosis, 2020
Background: High-quality epidemiologic data worldwide are needed to improve our understanding of disease risk, support health policy to meet the diverse needs of people with multiple sclerosis (MS) and support advocacy efforts.
Clare Walton, Rachel King, Lindsay Rechtman, W. Kaye, E. Leray, R. Marrie, N. Robertson, N. La Rocca, B. Uitdehaag, I. van der Mei, M. Wallin, A. Helme, Ceri Angood Napier, N. Rijke, P. Baneke   +14 more
semanticscholar   +1 more source

Disease‐Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis

Annals of Neurology, 2021
This study was undertaken to assess the impact of immunosuppressive and immunomodulatory therapies on the severity of coronavirus disease 2019 (COVID‐19) in people with multiple sclerosis (PwMS).
M. Sormani, N. de Rossi, I. Schiavetti, L. Carmisciano, C. Cordioli, L. Moiola, M. Radaelli, P. Immovilli, M. Capobianco, M. Trojano, P. Zaratin, G. Tedeschi, G. Comi, M. Battaglia, F. Patti, M. Salvetti   +15 more
semanticscholar   +1 more source

Multiple sclerosis

Medicine, 2008
Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS) and the most common cause of disability amongst young adults. The majority of patients present with a relapsing-remitting illness, characterized by discrete episodes of focal neurological deficit with temporal and anatomical dispersion in the CNS.
Wakerley, B, Nicholas, R, Malik, O
openaire   +6 more sources

Multiple sclerosis [PDF]

Mental Health Clinician, 2019
Abstract Multiple sclerosis is a chronic, unpredictable, and disabling disease. Significant advances have been made in recent years supporting an earlier, more accurate, diagnosis and have led to more than 15 disease-modifying therapies approved by the Food and Drug Administration for relapsing forms of multiple sclerosis.
Shilpa Klocke, Nicole Hahn
openaire   +2 more sources

COVID-19 Vaccine Response in People with Multiple Sclerosis Treated with Dimethyl Fumarate, Diroximel Fumarate, Natalizumab, Ocrelizumab, or Interferon Beta Therapy

Neurology and Therapy, 2023
Background Some multiple sclerosis (MS) disease-modifying therapies (DMTs) impair responses to vaccines, emphasizing the importance of understanding COVID-19 vaccine immune responses in people with MS (PwMS) receiving different DMTs.
Aliya Jaber, Meera Patel, Andrew Sylvester, Mary Yarussi, J. Tamar Kalina, Jason P. Mendoza, Robin L. Avila, Matthew A. Tremblay   +7 more
doaj   +1 more source

Gut Microbiome in Progressive Multiple Sclerosis

Annals of Neurology, 2021
This study was undertaken to investigate the gut microbiome in progressive multiple sclerosis (MS) and how it relates to clinical disease.
Laura M. Cox, A. Maghzi, Shirong Liu, Stephanie K. Tankou, Fyonn Dhang, Valerie Willocq, Anya Song, C. Wasén, S. Tauhid, R. Chu, Mark C. Anderson, P. D. De Jager, Mariann Polgar-Turcsanyi, B. Healy, B. Glanz, R. Bakshi, T. Chitnis, H. Weiner   +17 more
semanticscholar   +1 more source

“I need personal experiences or some sort of documentation”: a qualitative study on where people with multiple sclerosis seek information on dietary and herbal supplements

BMC Complementary Medicine and Therapies, 2021
Background The use of dietary and herbal supplements (DIHES) is widespread among people with multiple sclerosis (PwMS). PwMS are a highly informed patient group, and they use several types of sources to seek information on subjects related to their ...
Sofie Bergien, Clara M. Petersen, Marie Lynning, Maria Kristiansen, Lasse Skovgaard   +4 more
doaj   +1 more source

RAM-589.555 favors neuroprotective and anti-inflammatory profile of CNS-resident glial cells in acute relapse EAE affected mice

Journal of Neuroinflammation, 2020
Background Targeting RNA polymerase-1 (POL1) machinery is a new strategy for suppression of multiple sclerosis (MS) relapse activity. Oral administration of POL1 inhibitor RAM-589.555, which is characterized by high permeability and bioavailability in ...
Rina Zilkha-Falb, Tatyana Rachutin-Zalogin, Lakota Cleaver, Michael Gurevich, Anat Achiron   +4 more
doaj   +1 more source

Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

Annals of Neurology, 2011
New evidence and consensus has led to further revision of the McDonald Criteria for diagnosis of multiple sclerosis. The use of imaging for demonstration of dissemination of central nervous system lesions in space and time has been simplified, and in ...
C. Polman, S. Reingold, B. Banwell, M. Clanet, Jeffrey A. Cohen, M. Filippi, K. Fujihara, E. Havrdová, M. Hutchinson, L. Kappos, F. Lublin, X. Montalban, P. O'Connor, M. Sandberg-wollheim, A. Thompson, E. Waubant, B. Weinshenker, J. Wolinsky   +17 more
semanticscholar   +1 more source

The potential of serum neurofilament as biomarker for multiple sclerosis

Brain : a journal of neurology, 2021
Multiple sclerosis is a highly heterogeneous disease, and the detection of neuroaxonal damage as well as its quantification is a critical step for patients.
S. Bittner, Jiwon Oh, E. Havrdová, M. Tintoré, F. Zipp   +4 more
semanticscholar   +1 more source